Last update 31 Oct 2025

KD-6001

Overview

Basic Info

Drug Type
Biological products
Synonyms
KD 6001, KD-6001, KD6001
Target
CTLA4
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases
Active Indication
Hepatocellular CarcinomaLiver CancerMelanoma
Inactive Indication
Advanced Malignant Solid Neoplasm
Originator Organization
Shanghai Kangdai Biomedical Technology Co., Ltd.Shanghai Kangdai Biomedical Technology Co., Ltd.
Active Organization
Shanghai Celgen Bio-pharmaceutical Co., Ltd.Shanghai Celgen Bio-pharmaceutical Co., Ltd.Shanghai Kangdai Biomedical Technology Co., Ltd.Shanghai Kangdai Biomedical Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with KD-6001
NCT05906524
/ Not yet recruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KD6001 in Combination With Tislelizumab±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
NCT05723432
/ RecruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
NCT05230290
/ CompletedPhase 1
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
100 Clinical Results associated with KD-6001
Login to view more data
100 Translational Medicine associated with KD-6001
Login to view more data
100 Patents (Medical) associated with KD-6001
Login to view more data
100 Deals associated with KD-6001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 2
China
-15 Apr 2024
Liver CancerPhase 2
China
Shanghai Celgen Bio-pharmaceutical Co., Ltd.Shanghai Celgen Bio-pharmaceutical Co., Ltd.
13 Jul 2023
MelanomaPhase 2
China
Shanghai Celgen Bio-pharmaceutical Co., Ltd.Shanghai Celgen Bio-pharmaceutical Co., Ltd.
14 Mar 2023
Advanced Malignant Solid NeoplasmPhase 1
China
Shanghai Celgen Bio-pharmaceutical Co., Ltd.Shanghai Celgen Bio-pharmaceutical Co., Ltd.
10 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05230290 (ASCO2024)
ManualManual
Phase 1
Advanced Malignant Solid Neoplasm
13
KD6001 3mg/kg
mkfvtcotzn(oknhuivkmj) = Not observed. hainkgwbij (lrymqdxjtl )
View more
Positive
24 May 2024
KD6001 0.2,1,3,6mg/kg
NCT05723432 (KD6001CT02, ASCO2024)
ManualManual
Phase 1/2
Melanoma
29
mmgfszakib(asilmuzcnl) = unyknfgnbr whxckloxyo (ewbtlrblge )
View more
Positive
24 May 2024
(without brain metastases)
ooxbowagmv(lfcowyimmc) = mameusjyzk oqjboshltl (yajuafguro )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free